Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INCY Stock Forecast 2025-2026
$67.27
Current Price
$13.25B
Market Cap
Buy 11
Hold 15
Sell 1
Wall St Analyst Ratings
Distance to INCY Price Targets
+59.1%
To High Target of $107.00
+7.5%
To Median Target of $72.34
-22.7%
To Low Target of $52.00
INCY Price Momentum
-2.1%
1 Week Change
-2.2%
1 Month Change
+15.6%
1 Year Change
-2.6%
Year-to-Date Change
-19.9%
From 52W High of $83.95
+25.6%
From 52W Low of $53.56
📊 TOP ANALYST CALLS
Did INCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Incyte is one of their latest high-conviction picks.
Latest INCY Stock Price Targets & Analyst Predictions
Based on our analysis of 35 Wall Street analysts, INCY has a neutral consensus with a median price target of $72.34 (ranging from $52.00 to $107.00). The overall analyst rating is Buy (7.3/10). Currently trading at $67.27, the median forecast implies a 7.5% upside. This outlook is supported by 11 Buy, 15 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Stephen Willey at Stifel, projecting a 59.1% upside. Conversely, the most conservative target is provided by Evan Seigerman at BMO Capital, suggesting a 22.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCY Analyst Ratings
11
Buy
15
Hold
1
Sell
INCY Price Target Range
Low
$52.00
Average
$72.34
High
$107.00
Current: $67.27
Latest INCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 16, 2025 | Stifel | Stephen Willey | Buy | Upgrade | $107.00 |
| Jun 3, 2025 | UBS | Ashwani Verma | Neutral | Maintains | $61.00 |
| May 27, 2025 | Truist Securities | Srikripa Devarakonda | Hold | Maintains | $73.00 |
| Apr 30, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $59.00 |
| Apr 30, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $67.00 |
| Apr 21, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $68.00 |
| Mar 24, 2025 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $65.00 |
| Mar 18, 2025 | Guggenheim | Michael Schmidt | Neutral | Downgrade | $92.00 |
| Mar 18, 2025 | Truist Securities | Srikripa Devarakonda | Hold | Maintains | $72.00 |
| Mar 18, 2025 | William Blair | Y Katherine Xu | Market Perform | Downgrade | $0.00 |
| Mar 11, 2025 | Citizens Capital Markets | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Feb 11, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $88.00 |
| Feb 11, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Feb 11, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $68.00 |
| Feb 10, 2025 | Stifel | Stephen Willey | Hold | Maintains | $77.00 |
| Jan 23, 2025 | RBC Capital | Leonid Timashev | Sector Perform | Reiterates | $70.00 |
| Jan 14, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Jan 10, 2025 | Cantor Fitzgerald | Eric Schmidt | Neutral | Reiterates | $0.00 |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $70.00 |
| Dec 17, 2024 | UBS | Nicholas Holowko | Neutral | Assumes | $77.00 |
Incyte Corporation (INCY) Competitors
The following stocks are similar to Incyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Incyte Corporation (INCY) Financial Data
Incyte Corporation has a market capitalization of $13.25B with a P/E ratio of 342.2x. The company generates $4.41B in trailing twelve-month revenue with a 0.5% profit margin.
Revenue growth is +19.5% quarter-over-quarter, while maintaining an operating margin of +20.7% and return on equity of +0.5%.
Valuation Metrics
Market Cap
$13.25B
Enterprise Value
$10.82B
P/E Ratio
342.2x
PEG Ratio
11.1x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
+19.5%
Gross Margin
+93.0%
Operating Margin
+20.7%
Net Margin
+0.5%
EPS Growth
-6.7%
Financial Health
Cash/Price Ratio
+18.5%
Current Ratio
2.0x
Debt/Equity
1.2x
ROE
+0.5%
ROA
+2.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Incyte Corporation (INCY) Business Model
About Incyte Corporation
What They Do
Develops innovative therapeutics for oncology and inflammation.
Business Model
Incyte Corporation operates as a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics. The company generates revenue primarily through the sales of its proprietary compounds, particularly its leading product for blood cancers, while also investing in R&D to advance its pipeline of next-generation treatments.
Additional Information
Incyte has established strategic partnerships with major global pharmaceutical companies to enhance its research capabilities and market presence. The company is headquartered in Wilmington, Delaware, and plays a significant role in advancing medical science and patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,617
CEO
Mr. Herve Hoppenot
Country
United States
IPO Year
1993
Website
www.incyte.comIncyte Corporation (INCY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
Jul 01, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
INCY stock has increased by 9.2% over three months, driven by FDA approvals and a new diagnostic partnership enhancing its pipeline prospects.
Why It Matters
INCY's stock rise signals positive market sentiment driven by FDA approvals and strategic partnerships, enhancing growth potential and increasing investor confidence in future earnings.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Incyte's stock rose following the appointment of Bill Meury as CEO, replacing retiring Herve Hoppenot.
Why It Matters
A new CEO can signal potential strategic shifts, impacting company performance. Positive investor reaction to leadership changes may indicate confidence in future growth.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Incyte has appointed Bill Meury as CEO, succeeding Hervé Hoppenot, who is retiring.
Why It Matters
Leadership changes can impact company strategy and performance. Bill Meury's appointment may signal a shift in direction for Incyte, influencing investor sentiment and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The FDA has extended its review of Incyte's ruxolitinib cream for pediatric atopic dermatitis, pushing the decision date to September 2025.
Why It Matters
The FDA's delay on ruxolitinib cream signals potential setbacks for Incyte's growth and revenue, impacting stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Incyte's Opzelura cream review for treating moderate atopic dermatitis in children aged 2 to 11 has been extended by federal regulators.
Why It Matters
The extended review period for Opzelura may delay potential revenue and market entry, impacting Incyte's stock performance and future growth prospects.
Source: Market Watch
Market Sentiment:
Negative
Incyte Lymphoma Treatment Gets FDA Approval
19 days ago
Quick Summary
Incyte received FDA approval for Monjuvi, to be used with rituximab and lenalidomide, for treating follicular lymphoma.
Why It Matters
Incyte's FDA approval for Monjuvi boosts its product pipeline and potential revenue, positively impacting stock performance and attracting investor interest in oncology developments.
Source: Market Watch
Market Sentiment:
Positive
Frequently Asked Questions About INCY Stock
What is Incyte Corporation's (INCY) stock forecast for 2026?
Based on our analysis of 35 Wall Street analysts, Incyte Corporation (INCY) has a median price target of $72.34. The highest price target is $107.00 and the lowest is $52.00.
Is INCY stock a good investment in 2026?
According to current analyst ratings, INCY has 11 Buy ratings, 15 Hold ratings, and 1 Sell ratings. The stock is currently trading at $67.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INCY stock?
Wall Street analysts predict INCY stock could reach $72.34 in the next 12 months. This represents a 7.5% increase from the current price of $67.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Incyte Corporation's business model?
Incyte Corporation operates as a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics. The company generates revenue primarily through the sales of its proprietary compounds, particularly its leading product for blood cancers, while also investing in R&D to advance its pipeline of next-generation treatments.
What is the highest forecasted price for INCY Incyte Corporation?
The highest price target for INCY is $107.00 from Stephen Willey at Stifel, which represents a 59.1% increase from the current price of $67.27.
What is the lowest forecasted price for INCY Incyte Corporation?
The lowest price target for INCY is $52.00 from Evan Seigerman at BMO Capital, which represents a -22.7% decrease from the current price of $67.27.
What is the overall INCY consensus from analysts for Incyte Corporation?
The overall analyst consensus for INCY is neutral. Out of 35 Wall Street analysts, 11 rate it as Buy, 15 as Hold, and 1 as Sell, with a median price target of $72.34.
How accurate are INCY stock price projections?
Stock price projections, including those for Incyte Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 8:03 AM UTC